In vitro trypanocidal activity of DB745B and other novel arylimidamides against Trypanosoma cruzi

Cristiane França da Silva, Angela Junqueira, Marli Maria Lima, Alvaro José Romanha, Policarpo Ademar Sales Junior, Chad E. Stephens, Phanneth Som, David W. Boykin, Maria de Nazaré Correia Soeiro

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Objectives: As part of a search for newtherapeutic opportunities to treat chagasic patients, in vitro efficacy studies were performed to characterize the activity of five novel arylimidamides (AIAs) against Trypanosoma cruzi. Methods: The trypanocidal effect against T. cruziwas evaluated by light microscopy through the determination of IC50 values. Cytotoxicity was determined by MTT assays against mouse cardiomyocytes. Results: Our data demonstrated the trypanocidal efficacy of these new compounds against bloodstream trypomastigotes and intracellular amastigotes, exhibiting IC50 values ranging from 0.015 to 2.5 and 0.02 to 0.2 μM, respectively. One of the compounds, DB745B, was also highly active against a broad panel of isolates, including those naturally resistant to benznidazole. DB745B showed higher in vitro efficacy than the reference drugs used to treat patients (benznidazole IC50=12.94 μM) and to prevent blood bank infection (gentian violet IC50=30.6 μM). Conclusions: AIAs represent promising new chemical entities against T. cruzi and are also potential trypanocidal agents to prevent transfusion-associated Chagas' disease.

Original languageEnglish (US)
Article numberdkr140
Pages (from-to)1295-1297
Number of pages3
JournalJournal of Antimicrobial Chemotherapy
Volume66
Issue number6
DOIs
StatePublished - Jun 1 2011

Fingerprint

Trypanosoma cruzi
Inhibitory Concentration 50
Trypanocidal Agents
Gentian Violet
Blood Banks
Chagas Disease
Cardiac Myocytes
Microscopy
Light
In Vitro Techniques
Infection
Pharmaceutical Preparations
benzonidazole

Keywords

  • Chagas' disease
  • Chemotherapy
  • T. cruzi

ASJC Scopus subject areas

  • Pharmacology
  • Microbiology (medical)
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

da Silva, C. F., Junqueira, A., Lima, M. M., Romanha, A. J., Sales Junior, P. A., Stephens, C. E., ... de Nazaré Correia Soeiro, M. (2011). In vitro trypanocidal activity of DB745B and other novel arylimidamides against Trypanosoma cruzi. Journal of Antimicrobial Chemotherapy, 66(6), 1295-1297. [dkr140]. https://doi.org/10.1093/jac/dkr140

In vitro trypanocidal activity of DB745B and other novel arylimidamides against Trypanosoma cruzi. / da Silva, Cristiane França; Junqueira, Angela; Lima, Marli Maria; Romanha, Alvaro José; Sales Junior, Policarpo Ademar; Stephens, Chad E.; Som, Phanneth; Boykin, David W.; de Nazaré Correia Soeiro, Maria.

In: Journal of Antimicrobial Chemotherapy, Vol. 66, No. 6, dkr140, 01.06.2011, p. 1295-1297.

Research output: Contribution to journalArticle

da Silva, CF, Junqueira, A, Lima, MM, Romanha, AJ, Sales Junior, PA, Stephens, CE, Som, P, Boykin, DW & de Nazaré Correia Soeiro, M 2011, 'In vitro trypanocidal activity of DB745B and other novel arylimidamides against Trypanosoma cruzi', Journal of Antimicrobial Chemotherapy, vol. 66, no. 6, dkr140, pp. 1295-1297. https://doi.org/10.1093/jac/dkr140
da Silva, Cristiane França ; Junqueira, Angela ; Lima, Marli Maria ; Romanha, Alvaro José ; Sales Junior, Policarpo Ademar ; Stephens, Chad E. ; Som, Phanneth ; Boykin, David W. ; de Nazaré Correia Soeiro, Maria. / In vitro trypanocidal activity of DB745B and other novel arylimidamides against Trypanosoma cruzi. In: Journal of Antimicrobial Chemotherapy. 2011 ; Vol. 66, No. 6. pp. 1295-1297.
@article{eff3323c6e5d4ddcb310fcbd306ea4e7,
title = "In vitro trypanocidal activity of DB745B and other novel arylimidamides against Trypanosoma cruzi",
abstract = "Objectives: As part of a search for newtherapeutic opportunities to treat chagasic patients, in vitro efficacy studies were performed to characterize the activity of five novel arylimidamides (AIAs) against Trypanosoma cruzi. Methods: The trypanocidal effect against T. cruziwas evaluated by light microscopy through the determination of IC50 values. Cytotoxicity was determined by MTT assays against mouse cardiomyocytes. Results: Our data demonstrated the trypanocidal efficacy of these new compounds against bloodstream trypomastigotes and intracellular amastigotes, exhibiting IC50 values ranging from 0.015 to 2.5 and 0.02 to 0.2 μM, respectively. One of the compounds, DB745B, was also highly active against a broad panel of isolates, including those naturally resistant to benznidazole. DB745B showed higher in vitro efficacy than the reference drugs used to treat patients (benznidazole IC50=12.94 μM) and to prevent blood bank infection (gentian violet IC50=30.6 μM). Conclusions: AIAs represent promising new chemical entities against T. cruzi and are also potential trypanocidal agents to prevent transfusion-associated Chagas' disease.",
keywords = "Chagas' disease, Chemotherapy, T. cruzi",
author = "{da Silva}, {Cristiane Fran{\cc}a} and Angela Junqueira and Lima, {Marli Maria} and Romanha, {Alvaro Jos{\'e}} and {Sales Junior}, {Policarpo Ademar} and Stephens, {Chad E.} and Phanneth Som and Boykin, {David W.} and {de Nazar{\'e} Correia Soeiro}, Maria",
year = "2011",
month = "6",
day = "1",
doi = "10.1093/jac/dkr140",
language = "English (US)",
volume = "66",
pages = "1295--1297",
journal = "Journal of Antimicrobial Chemotherapy",
issn = "0305-7453",
publisher = "Oxford University Press",
number = "6",

}

TY - JOUR

T1 - In vitro trypanocidal activity of DB745B and other novel arylimidamides against Trypanosoma cruzi

AU - da Silva, Cristiane França

AU - Junqueira, Angela

AU - Lima, Marli Maria

AU - Romanha, Alvaro José

AU - Sales Junior, Policarpo Ademar

AU - Stephens, Chad E.

AU - Som, Phanneth

AU - Boykin, David W.

AU - de Nazaré Correia Soeiro, Maria

PY - 2011/6/1

Y1 - 2011/6/1

N2 - Objectives: As part of a search for newtherapeutic opportunities to treat chagasic patients, in vitro efficacy studies were performed to characterize the activity of five novel arylimidamides (AIAs) against Trypanosoma cruzi. Methods: The trypanocidal effect against T. cruziwas evaluated by light microscopy through the determination of IC50 values. Cytotoxicity was determined by MTT assays against mouse cardiomyocytes. Results: Our data demonstrated the trypanocidal efficacy of these new compounds against bloodstream trypomastigotes and intracellular amastigotes, exhibiting IC50 values ranging from 0.015 to 2.5 and 0.02 to 0.2 μM, respectively. One of the compounds, DB745B, was also highly active against a broad panel of isolates, including those naturally resistant to benznidazole. DB745B showed higher in vitro efficacy than the reference drugs used to treat patients (benznidazole IC50=12.94 μM) and to prevent blood bank infection (gentian violet IC50=30.6 μM). Conclusions: AIAs represent promising new chemical entities against T. cruzi and are also potential trypanocidal agents to prevent transfusion-associated Chagas' disease.

AB - Objectives: As part of a search for newtherapeutic opportunities to treat chagasic patients, in vitro efficacy studies were performed to characterize the activity of five novel arylimidamides (AIAs) against Trypanosoma cruzi. Methods: The trypanocidal effect against T. cruziwas evaluated by light microscopy through the determination of IC50 values. Cytotoxicity was determined by MTT assays against mouse cardiomyocytes. Results: Our data demonstrated the trypanocidal efficacy of these new compounds against bloodstream trypomastigotes and intracellular amastigotes, exhibiting IC50 values ranging from 0.015 to 2.5 and 0.02 to 0.2 μM, respectively. One of the compounds, DB745B, was also highly active against a broad panel of isolates, including those naturally resistant to benznidazole. DB745B showed higher in vitro efficacy than the reference drugs used to treat patients (benznidazole IC50=12.94 μM) and to prevent blood bank infection (gentian violet IC50=30.6 μM). Conclusions: AIAs represent promising new chemical entities against T. cruzi and are also potential trypanocidal agents to prevent transfusion-associated Chagas' disease.

KW - Chagas' disease

KW - Chemotherapy

KW - T. cruzi

UR - http://www.scopus.com/inward/record.url?scp=79956028472&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79956028472&partnerID=8YFLogxK

U2 - 10.1093/jac/dkr140

DO - 10.1093/jac/dkr140

M3 - Article

C2 - 21478242

AN - SCOPUS:79956028472

VL - 66

SP - 1295

EP - 1297

JO - Journal of Antimicrobial Chemotherapy

JF - Journal of Antimicrobial Chemotherapy

SN - 0305-7453

IS - 6

M1 - dkr140

ER -